top of page

Evana® Wins ‘Product Launch of the Year’
at Pharmacy Product of the Year Awards 

Alderley Park, UK – March 14 2025 – Maxwellia is proud to announce that Evana®, the only over-the-counter treatment for heavy periods, has won ‘Product Launch of the Year’ at the prestigious Pharmacy Product of the Year Awards 2025.

This award celebrates Maxwellia’s dedication to empowering pharmacy teams with innovative self-care medicines that address unmet needs. It also highlights the impact of Evana’s pharmacy marketing campaign in raising awareness of heavy menstrual bleeding and the availability of this new pharmacy brand.

Heavy menstrual bleeding (HMB) has been estimated to affect up to 30% of women[1]. While a recent survey of 3,000 women and girls commissioned by the Wellbeing of Women charity reported that heavy periods affected 91% of respondents, with nearly half describing their bleeding as severe[2]. Yet, despite its prevalence, HMB is often overlooked, leaving many women suffering in silence. The condition also carries a significant economic cost—absenteeism due to HMB costs the UK economy £4.7 billion annually[3].

Evana was developed to address a significant unmet need providing women with a more accessible and convenient way to manage their heavy period symptoms. Since launch, the brand has been supported by a comprehensive pharmacy training programme, events, and above-the-line advertising campaigns to ensure pharmacy teams not only recognise the brand but also feel confident in recommending it to their customers. With the recent rollout of a TV campaign, consumer awareness continues to build, further cementing Evana’s role as a recognised name in women’s health.

Evana packshot with PPOTY logo.png

Commenting on the win, Anna Maxwell, Founder and CEO at Maxwellia, said: "Winning this award is a testament to our mission of widening access to medicines and empowering women to manage their health through self-care. Heavy periods impact millions of women, and yet all too often their symptoms are dismissed, and they struggle to access appropriate treatments. With Evana now widely available in pharmacy we’re challenging the status quo. By supporting pharmacists with the right products, tools and training, we’re making a real difference in women’s health."

Maxwellia’s Head of Marketing, Kim Wathall added: "This award reflects the incredible work that has gone into making Evana a success; from identifying the unmet need and opportunity for pharmacy, to the comprehensive awareness, education and training campaign delivered to pharmacy teams. We are thrilled to see Evana gaining recognition as a trusted brand in women’s health in such a short time."

Maxwellia remains committed to empowering pharmacy teams with innovative treatments that support self-care and drive category growth. The success of Evana demonstrates the vital role of pharmacy in providing accessible healthcare solutions.

Evana® is available to order from leading wholesalers, and you can access our comprehensive pharmacy training materials online.

References:

 

1. Cox, M, et al. The delivery of heavy menstrual bleeding services in England and Wales after publication of national guidelines: a survey of hospitals. BMC Health Services Res. 2013; 13:491.
2. Wellbeing of Women, Just a Period Campaign 
3. NHS Confederation, Women's Health Economics

Evana® Heavy Period Relief 500mg tablets. Tranexamic acid. Maxwellia Ltd. P. Reduction of heavy menstrual bleeding over several cycles in women with regular, 21-35 day cycles with no more than 3 day variation. For full information see: evanaperiods.com/hcp/evana/smpc.

bottom of page